Carlo Napolitano

List of Publications by Citations

235 papers	26,469 citations	79 h-index	161 g-index
281 ext. papers	29,805 ext. citations	10 avg, IF	6.26 L-index

#	Paper	IF	Citations
235	Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation*, **2001**, 103, 89-95	16.7	1363
234	Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell*, **2004**, 119, 19-31	56.2	1182
233	Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2001**, 103, 196-200	16.7	1101
232	Risk stratification in the long-QT syndrome. *New England Journal of Medicine*, **2003**, 348, 1866-74	59.2	1090
231	Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2002**, 106, 69-74	16.7	937
230	Natural history of Brugada syndrome: insights for risk stratification and management. *Circulation*, **2002**, 105, 1342-7	16.7	805
229	Low penetrance in the long-QT syndrome: clinical impact. *Circulation*, **1999**, 99, 529-33	16.7	650
228	Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. *Circulation*, **2000**, 101, 616-23	16.7	646
227	Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. *New England Journal of Medicine*, **1998**, 339, 960-5	59.2	628
226	FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. *Cell*, **2003**, 113, 829-40	56.2	589
225	Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. *Circulation*, **1995**, 92, 3381-6	16.7	532
224	Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. *Circulation*, **2004**, 109, 1826-33	16.7	503
223	A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. *Circulation Research*, **2005**, 96, 800-7	15.7	495
222	Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. *JAMA - Journal of the American Medical Association*, **2004**, 292, 1341-4	27.4	445
221	Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. *Circulation*, **2000**, 102, 2509-15	16.7	420
220	Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. *Journal of the American College of Cardiology*, **2012**, 59, 37-45	15.1	409
219	Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. *Circulation*, **1998**, 97, 2237-44	16.7	377

218	Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. *Circulation*, **2000**, 102, 2849-55	16.7	352
217	Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. *JAMA - Journal of the American Medical Association*, **2005**, 294, 2975-80	27.4	346
216	Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. *Circulation*, **1994**, 89, 1681-9	16.7	321
215	Long QT syndrome in adults. *Journal of the American College of Cardiology*, **2007**, 49, 329-37	15.1	311
214	Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 17533-8	11.5	299
213	Venice Chart international consensus document on atrial fibrillation ablation. *Journal of Cardiovascular Electrophysiology*, **2007**, 18, 560-80	2.7	298
212	A molecular link between the sudden infant death syndrome and the long-QT syndrome. *New England Journal of Medicine*, **2000**, 343, 262-7	59.2	296
211	Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. *Journal of Cardiovascular Electrophysiology*, **2000**, 11, 691-6	2.7	280
210	Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. *Circulation*, **2005**, 112, 3680-7	16.7	267
209	A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 9137-42	11.5	264
208	Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. *Circulation Research*, **2006**, 99, 292-8	15.7	256
207	Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. *Circulation*, **2014**, 129, 1092-103	16.7	242
206	High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". *Circulation*, **2009**, 119, 215-21	16.7	235
205	Long QT syndrome and pregnancy. *Journal of the American College of Cardiology*, **2007**, 49, 1092-8	15.1	233
204	Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. *Circulation*, **2008**, 117, 2184-91	16.7	229
203	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. *Journal of the American College of Cardiology*, **2003**, 42, 103-9	15.1	224
202	Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. *JAMA - Journal of the American Medical Association*, **2006**, 296, 1249-54	27.4	216
201	Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2007**, 101, 1039-48	15.7	215

200	The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. *Circulation*, **2000**, 102, 945-7	16.7	211
199	Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. *Journal of the American College of Cardiology*, **2011**, 57, 51-9	15.1	205
198	Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. *Circulation Research*, **2005**, 96, e77-82	15.7	204
197	Brugada syndrome and sudden cardiac death in children. *Lancet, The*, **2000**, 355, 808-9	40	198
196	Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. *American Journal of Cardiology*, **1999**, 84, 876-9	3	186
195	Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. *Journal of the American College of Cardiology*, **2003**, 41, 633-42	15.1	179
194	Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2006**, 114, 1012-9	16.7	169
193	Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. *Circulation Research*, **2006**, 98, 1151-8	15.7	163
192	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. *Journal of Clinical Investigation*, **2002**, 110, 1201-1209	15.9	162
191	Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. *Circulation*, **2007**, 116, 1137-44	16.7	159
190	Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. *Circulation*, **2005**, 112, 279-92; discussion 279-92	16.7	154
189	Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. *Journal of Biological Chemistry*, **2001**, 276, 30623-30	5.4	151
188	Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome. *Human Molecular Genetics*, **1999**, 8, 1499-507	5.6	149
187	Novel insight into the natural history of short QT syndrome. *Journal of the American College of Cardiology*, **2014**, 63, 1300-1308	15.1	147
186	Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. *Circulation Research*, **2004**, 94, 471-7	15.7	147
185	Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. *Journal of the American College of Cardiology*, **2010**, 55, 2745-52	15.1	143
184	Inherited calcium channelopathies in the pathophysiology of arrhythmias. *Nature Reviews Cardiology*, **2012**, 9, 561-75	14.8	139
183	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis. *Circulation*, **2016**, 133, 622-30	16.7	138

182	Molecular diagnosis in a child with sudden infant death syndrome. *Lancet, The*, **2001**, 358, 1342-3	40	135
181	Catecholaminergic polymorphic ventricular tachycardia. *Progress in Cardiovascular Diseases*, **2008**, 51, 23-30	8.5	130
180	Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. *European Heart Journal*, **2009**, 30, 2241-8	9.5	128
179	Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. *Journal of the American College of Cardiology*, **2016**, 67, 1053-1058	15.1	123
178	A recessive variant of the Romano-Ward long-QT syndrome?. *Circulation*, **1998**, 97, 2420-5	16.7	120
177	Long-QT syndrome after age 40. *Circulation*, **2008**, 117, 2192-201	16.7	117
176	SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. *Heart Rhythm*, **2020**, 17, 1456-1462	6.7	115
175	Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. *Circulation Research*, **1996**, 78, 1009-15	15.7	115
174	Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2009**, 104, 201-9, 12p following 209	15.7	114
173	Evaluation of the spatial aspects of T-wave complexity in the long-QT syndrome. *Circulation*, **1997**, 96, 3006-12	16.7	114
172	Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. *Circulation: Arrhythmia and Electrophysiology*, **2009**, 2, 6-15	6.4	111
171	Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. *Circulation Research*, **2008**, 103, 298-306	15.7	110
170	Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2007**, 4, 675-8	6.7	109
169	Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel. *Circulation Research*, **2001**, 88, 740-5	15.7	105
168	Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. *Journal of Cardiovascular Electrophysiology*, **2007**, 18, 791-7	2.7	101
167	Torsade de pointes. Mechanisms and management. *Drugs*, **1994**, 47, 51-65	12.1	100
166	Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk. *Journal of the American College of Cardiology*, **2016**, 68, 2540-2550	15.1	99
165	Sudden cardiac death and genetic ion channelopathies: long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation. *Circulation*, **2012**, 125, 2027-34	16.7	97

164	How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1120-1	2.7	96
163	Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. *Journal of Molecular and Cellular Cardiology* , **2011**, 50, 214-22	5.8	95
162	CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. *Cell Death and Disease*, **2013**, 4, e843	9.8	92
161	Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation. *Heart Rhythm*, **2009**, 6, 1652-9	6.7	90
160	Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. *European Heart Journal*, **2002**, 23, 975-83	9.5	90
159	A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 407-11	2.7	89
158	Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. *Journal of the American College of Cardiology*, **2011**, 57, 941-50	15.1	84
157	Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. *Circulation Research*, **2011**, 109, 291-5	15.7	84
156	Role of genetic analyses in cardiology: part I: mendelian diseases: cardiac channelopathies. *Circulation*, **2006**, 113, 1130-5	16.7	79
155	Flecainide test in Brugada syndrome: a reproducible but risky tool. *PACE - Pacing and Clinical Electrophysiology*, **2003**, 26, 338-41	1.6	79
154	Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. *Journal of the American College of Cardiology*, **2018**, 71, 1663-1671	15.1	76
153	In the RyR2(R4496C) mouse model of CPVT, adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves. *Circulation Research*, **2010**, 107, 1483-9	15.7	76
152	Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. *Cardiovascular Research*, **2010**, 87, 50-9	9.9	74
151	Electrocardiographic prediction of abnormal genotype in congenital long QT syndrome: experience in 101 related family members. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 455-61	2.7	74
150	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H1748-56	5.2	74
149	Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. *Journal of the American College of Cardiology*, **2009**, 54, 832-7	15.1	70
148	Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. *Journal of Clinical Investigation*, **2005**, 115, 2033-8	15.9	70
147	Genetics of cardiac arrhythmias and sudden cardiac death. *Annals of the New York Academy of Sciences*, **2004**, 1015, 96-110	6.5	69

146	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. *Journal of Clinical Investigation*, **2002**, 110, 1201-9	15.9	67
145	Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome. *Circulation*, **1999**, 99, 1344-7	16.7	65
144	Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. *Circulation*, **2014**, 129, 2673-81	16.7	64
143	Female predominance and transmission distortion in the long-QT syndrome. *New England Journal of Medicine*, **2006**, 355, 2744-51	59.2	63
142	Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1149-53	2.7	63
141	Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. *Circulation Research*, **2010**, 106, 1374-83	15.7	61
140	Clinical implications for affected parents and siblings of probands with long-QT syndrome. *Circulation*, **2001**, 104, 557-62	16.7	61
139	Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. *American Journal of Cardiology*, **2000**, 85, 457-61	3	61
138	Cardiac receptor activation and arrhythmogenesis. *European Heart Journal*, **1993**, 14 Suppl E, 20-6	9.5	61
137	Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel. *Circulation Research*, **2011**, 108, 607-18	15.7	60
136	Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2012**, 126, 392-401	16.7	59
135	Early afterdepolarizations induced in vivo by reperfusion of ischemic myocardium. A possible mechanism for reperfusion arrhythmias. *Circulation*, **1990**, 81, 1911-20	16.7	59
134	Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. *British Journal of Cancer*, **2015**, 112, 1011-6	8.7	57
133	Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias. *Circulation Research*, **2012**, 110, 663-8	15.7	55
132	Risk of death in the long QT syndrome when a sibling has died. *Heart Rhythm*, **2008**, 5, 831-6	6.7	55
131	ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. *European Heart Journal*, **2004**, 25, 437-45	9.5	53
130	Mechanisms of I(Ks) suppression in LQT1 mutants. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H3003-11	5.2	53
129	Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. *Journal of Clinical Investigation*, **2013**, 123, 84-91	15.9	53

128	Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autism-epilepsy phenotype. *Human Molecular Genetics*, **2014**, 23, 4875-86	5.6	52
127	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. *Heart Rhythm*, **2018**, 15, 1394-1401	6.7	49
126	Therapeutic strategies for long-QT syndrome: does the molecular substrate matter?. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 290-7	6.4	49
125	Programmed electrical stimulation in Brugada syndrome: how reproducible are the results?. *Journal of Cardiovascular Electrophysiology*, **2002**, 13, 880-7	2.7	47
124	Assessment of a personalized and distributed patient guidance system. *International Journal of Medical Informatics*, **2017**, 101, 108-130	5.3	44
123	Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca2+ release in a genetic model of arrhythmia. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 10312-7	11.5	42
122	Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. *Journal of the American College of Cardiology*, **2017**, 70, 3010-3015	15.1	41
121	Age of First Arrhythmic Event in Brugada Syndrome: Data From the SABRUS (Survey on Arrhythmic Events in Brugada Syndrome) in 678 Patients. *Circulation: Arrhythmia and Electrophysiology*, **2017**, 10,	6.4	39
120	Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. *Journal of the American College of Cardiology*, **1995**, 25, 1609-14	15.1	39
119	Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 300, H288-99	5.2	38
118	Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. *Cell Death and Disease*, **2016**, 7, e2393	9.8	37
117	Subclinical abnormalities in sarcoplasmic reticulum Ca(2+) release promote eccentric myocardial remodeling and pump failure death in response to pressure overload. *Journal of the American College of Cardiology*, **2014**, 63, 1569-79	15.1	37
116	Abnormal propagation of calcium waves and ultrastructural remodeling in recessive catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2013**, 113, 142-52	15.7	37
115	Lateritic crusts and related soils in eastern Brazilian Amazonia. *Geoderma*, **2005**, 126, 225-239	6.7	37
114	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). *Heart Rhythm*, **2018**, 15, 716-724	6.7	36
113	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. *Heart Rhythm*, **2018**, 15, 1457-1465	6.7	36
112	Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (). *Circulation Research*, **2017**, 121, 525-536	15.7	33
111	Pathogenesis and therapy of the idiopathic long QT syndrome. *Annals of the New York Academy of Sciences*, **1992**, 644, 112-41	6.5	33

110	Molecular biology of the long QT syndrome: impact on management. *PACE - Pacing and Clinical Electrophysiology*, **1997**, 20, 2052-7	1.6	32
109	The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. *Expert Review of Cardiovascular Therapy*, **2014**, 12, 499-519	2.5	31
108	Genetics and arrhythmias: diagnostic and prognostic applications. *Revista Espanola De Cardiologia*, **2012**, 65, 278-86	1.5	31
107	Genetics of ion-channel disorders. *Current Opinion in Cardiology*, **2012**, 27, 242-52	2.1	30
106	MobiGuide: a personalized and patient-centric decision-support system and its evaluation in the atrial fibrillation and gestational diabetes domains. *User Modeling and User-Adapted Interaction*, **2017**, 27, 159-213	3.9	29
105	Overexpression of CaMKII in RyR2R4496C+/- knock-in mice leads to altered intracellular Ca2+ handling and increased mortality. *Journal of the American College of Cardiology*, **2011**, 57, 469-79	15.1	28
104	Brugada syndrome. *Orphanet Journal of Rare Diseases*, **2006**, 1, 35	4.2	28
103	Concealed arrhythmogenic syndromes: the hidden substrate of idiopathic ventricular fibrillation?. *Cardiovascular Research*, **2001**, 50, 218-23	9.9	28
102	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. *Circulation*, **2020**, 142, 324-338	16.7	27
101	Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. *Circulation*, **2020**, 142, 513-515	16.7	26
100	Late gadolinium enhancement by cardiovascular magnetic resonance is complementary to left ventricle ejection fraction in predicting prognosis of patients with stable coronary artery disease. *Journal of Cardiovascular Magnetic Resonance*, **2012**, 14, 29	6.9	26
99	Long QT syndrome and short QT syndrome: how to make correct diagnosis and what about eligibility for sports activity. *Journal of Cardiovascular Medicine*, **2006**, 7, 250-6	1.9	25
98	Inherited arrhythmia syndromes: applying the molecular biology and genetic to the clinical management. *Journal of Interventional Cardiac Electrophysiology*, **2003**, 9, 93-101	2.4	25
97	Intracellular calcium handling dysfunction and arrhythmogenesis: a new challenge for the electrophysiologist. *Circulation Research*, **2005**, 97, 1077-9	15.7	25
96	Policy statement: ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. *Resuscitation*, **2004**, 60, 245-52	4	24
95	Cardiac sodium channel diseases. *Clinical Chemistry and Laboratory Medicine*, **2003**, 41, 439-44	5.9	24
94	Gene-specific therapy for inherited arrhythmogenic diseases **2006**, 110, 1-13		23
93	From decision to shared-decision: Introducing patientsPpreferences into clinical decision analysis. *Artificial Intelligence in Medicine*, **2015**, 65, 19-28	7.4	21

92	Brugada syndrome. *International Journal of Cardiology*, **2005**, 101, 173-8	3.2	21
91	In silico assessment of Y1795C and Y1795H SCN5A mutations: implication for inherited arrhythmogenic syndromes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H56-65	5.2	20
90	Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes. *Cardiovascular Drugs and Therapy*, **2002**, 16, 89-92	3.9	20
89	International Triadin Knockout Syndrome Registry. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002419	5.2	20
88	Significance of QT dispersion in the long QT syndrome. *Progress in Cardiovascular Diseases*, **2000**, 42, 345-50	8.5	19
87	Recruitment of the TATA-binding protein to the HIV-1 promoter is a limiting step for Tat transactivation. *Aids*, **1998**, 12, 1957-64	3.5	19
86	Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. *Journal of the American College of Cardiology*, **2020**, 75, 1772-1784	15.1	18
85	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. *Europace*, **2021**, 23, 147-148	3.9	18
84	Cardiac ryanodine receptor calcium release deficiency syndrome. *Science Translational Medicine*, **2021**, 13,	17.5	18
83	Genetic modulators of the phenotype in the long QT syndrome: state of the art and clinical impact. *Current Opinion in Genetics and Development*, **2015**, 33, 17-24	4.9	17
82	Noninvasive quantification of blood potassium concentration from ECG in hemodialysis patients. *Scientific Reports*, **2017**, 7, 42492	4.9	16
81	Electrophysiologic mechanisms involved in the development of torsades de pointes. *Cardiovascular Drugs and Therapy*, **1991**, 5, 203-12	3.9	16
80	Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome. *Europace*, **2018**, 20, 234-242	3.9	15
79	R engine cell: integrating R into the i2b2 software infrastructure. *Journal of the American Medical Informatics Association: JAMIA*, **2011**, 18, 314-7	8.6	14
78	Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. *Journal of Cardiovascular Electrophysiology*, **2016**, 27, 937-43	2.7	14
77	Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT). *European Journal of Human Genetics*, **2014**, 22,	5.3	13
76	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. *Genetics in Medicine*, **2021**, 23, 47-58	8.1	13
75	Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. *Circulation*, **2005**, 112, 279-92; discussion 279-92	16.7	12

74	Unusual retrospective prenatal findings in a male newborn with Timothy syndrome type 1. *European Journal of Medical Genetics*, **2015**, 58, 332-5	2.6	11
73	Information extraction from Italian medical reports: An ontology-driven approach. *International Journal of Medical Informatics*, **2018**, 111, 140-148	5.3	11
72	CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases. *Human Mutation*, **2018**, 39, 1835-1846	4.7	11
71	RyRCa2+ leak limits cardiac Ca2+ window current overcoming the tonic effect of calmodulinin mice. *PLoS ONE*, **2011**, 6, e20863	3.7	10
70	The genetics of cardiomyopathy: genotyping and genetic counseling. *Current Treatment Options in Cardiovascular Medicine*, **2009**, 11, 433-46	2.1	10
69	Supervised methods to extract clinical events from cardiology reports in Italian. *Journal of Biomedical Informatics*, **2019**, 95, 103219	10.2	9
68	Graphical representation of life paths to better convey results of decision models to patients. *Medical Decision Making*, **2015**, 35, 398-402	2.5	9
67	Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Trends in Cardiovascular Medicine*, **2012**, 22, 35-9	6.9	9
66	Computer simulation of wild-type and mutant human cardiac Na+ current. *Medical and Biological Engineering and Computing*, **2006**, 44, 35-44	3.1	9
65	Genetics of ventricular tachycardia. *Current Opinion in Cardiology*, **2002**, 17, 222-8	2.1	9
64	Genetics of Long QT, Brugada, and Other Channelopathies **2004**, 462-470		8
63	Catecholaminergic Polymorphic Ventricular Tachycardia and Short-coupled Torsades de Pointes **2004**, 633-639		8
62	The influence of Generalized Anxiety Disorder on Executive Functions in children with ADHD. *European Archives of Psychiatry and Clinical Neuroscience*, **2018**, 268, 349-357	5.1	8
61	J-Wave Syndromes: Electrocardiographic and Clinical Aspects. *Cardiac Electrophysiology Clinics*, **2018**, 10, 355-369	1.4	8
60	Genetic testing of inherited arrhythmias. *Pediatric Cardiology*, **2012**, 33, 980-7	2.1	7
59	Risk stratification in the long-QT syndrome. *New England Journal of Medicine*, **2003**, 349, 908-9; author reply 908-9	59.2	7
58	Supporting shared decision making within the MobiGuide project **2013**, 2013, 1175-84	0.7	7
57	Interplay between Clinical Guidelines and Organizational Workflow Systems. Experience from the MobiGuide Project. *Methods of Information in Medicine*, **2016**, 55, 488-494	1.5	7

56	Multivariate Methods for Genetic Variants Selection and Risk Prediction in Cardiovascular Diseases. *Frontiers in Cardiovascular Medicine*, **2016**, 3, 17	5.4	7
55	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). *Europace*, **2019**, 21, 796-802	3.9	7
54	Role of calmodulin kinase in catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2011**, 8, 1601-5	6.7	6
53	When is genetic testing useful in patients suspected to have inherited cardiac arrhythmias?. *Current Opinion in Cardiology*, **2010**, 25, 37-45	2.1	6
52	Torsade de pointes. *Emergency Medicine Journal*, **2002**, 19, 485-6	1.5	6
51	Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death. *Bioscience Reports*, **2021**, 41,	4.1	6
50	Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the Gene Associated With Brugada Syndrome. *Frontiers in Physiology*, **2020**, 11, 616819	4.6	6
49	Patient-tailored workflow patterns from clinical practice guidelines recommendations. *Studies in Health Technology and Informatics*, **2013**, 192, 392-6	0.5	6
48	Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2019**, 12,	6.4	5
47	Early phase telemedicine requirements elicitation in collaboration with medical practitioners **2013**,		5
46	Genetic risk stratification in cardiac arrhythmias. *Current Opinion in Cardiology*, **2018**, 33, 298-303	2.1	4
45	Recurrent Neural Network Architectures for Event Extraction from Italian Medical Reports. *Lecture Notes in Computer Science*, **2017**, 198-202	0.9	4
44	Challenges in Molecular Diagnostics of Channelopathies in the Next-Generation Sequencing Era: Less Is More?. *Frontiers in Cardiovascular Medicine*, **2016**, 3, 29	5.4	4
43	Unexpected Risk Profile of a Large Pediatric Population With Brugada Syndrome. *Journal of the American College of Cardiology*, **2019**, 73, 1868-1869	15.1	3
42	Congenital Long QT Syndrome Type 3. *Cardiac Electrophysiology Clinics*, **2014**, 6, 705-713	1.4	3
41	Letter regarding article by Coronel et al, "right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study". *Circulation*, **2006**, 113, e726; author reply 726-7	16.7	3
40	Magnetocardiographic findings and follow-up in an asymptomatic Brugada patient. Effects of Flecainide and of exercise tests. *International Congress Series*, **2007**, 1300, 459-462		3
39	Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With Blockers.. *JAMA Cardiology*, **2022**,	16.2	3

38	Action potential changes due to Y1795H mutation in Brugada syndrome patients: a simulation study **2003**,		2
37	Markovian model for wild-type and mutant (Y1795C and Y1795H) human cardiac Na/sup +/ channel **2003**,		2
36	Cardiac Magnetic Resonance in Stable Coronary Artery Disease: Added Prognostic Value to Conventional Risk Profiling. *BioMed Research International*, **2018**, 2018, 2806148	3	2
35	Reply: Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3?. *Journal of the American College of Cardiology*, **2017**, 69, 248-249	15.1	1
34	Timothy Syndrome **2014**, 953-957		1
33	Risk Stratification in the Long QT Syndrome. *Cardiac Electrophysiology Clinics*, **2012**, 4, 53-60	1.4	1
32	Genetics for the Electrophysiologist: Take Home Messages for the Clinician. *Cardiac Electrophysiology Clinics*, **2010**, 2, 623-634	1.4	1
31	Just another Brugada syndrome mutation?. *Heart Rhythm*, **2007**, 4, 54-5	6.7	1
30	Transgenic models in cardiac arrhythmias: how close can we get to the bedside?. *Cardiovascular Research*, **2004**, 61, 206-7	9.9	1
29	Romano-Ward and other congenital long QT syndromes. *Cardiovascular Drugs and Therapy*, **2002**, 16, 19-23	3.9	1
28	Tyrosine kinase inhibitors and QTc intervals: A class effect.. *Journal of Clinical Oncology*, **2014**, 32, 2590-2590	2.2	1
27	Genetic and Molecular Basis of Arrhythmias **2011**, 65-86		1
26	Is mexiletine ready for prime time in patients with Type 2 Long QT Syndrome?. *European Heart Journal*, **2020**, 41,	9.5	1
25	L-Type Calcium Channel Disease **2013**, 209-217		1
24	Clinical and research data integration: the i2b2-FSM experience. *AMIA Summits on Translational Science Proceedings*, **2013**, 2013, 239-40	1.1	1
23	Timothy Syndrome **2018**, 910-916		0
22	Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome.. *Circulation Genomic and Precision Medicine*, **2022**, CIRCGEN121003391	5.2	0
21	Identification of a SCN5A founder mutation causing sudden death, Brugada syndrome, and conduction blocks in Southern Italy. *Heart Rhythm*, **2021**, 18, 1698-1706	6.7	0

20	Gene Therapy to Treat Cardiac Arrhythmias **2018**, 531-540	
19	Sodium Current Disorders. *Cardiac Electrophysiology Clinics*, **2014**, 6, 825-833	1.4
18	Genetics and Arrhythmias: Diagnostic and Prognostic Applications. *Revista Espanola De Cardiologia (English Ed)*, **2012**, 65, 278-286	0.7
17	Genetic Mechanisms of Arrhythmia **2012**, 601-623	
16	Intracellular Calcium Handling and Inherited Arrhythmogenic Diseases **2011**, 387-408	
15	The heritable nature of the electrocardiogram: How far can population genetics go?. *Heart Rhythm*, **2009**, 6, 642-3	6.7
14	Genetics, genomics and proteomics in sudden cardiac death70-89	
13	L-type Calcium Channel Disease **2008**, 187-193	
12	Catecholaminergic Polymorphic Ventricular Tachycardia **2008**, 536-544	
11	Will the Spectrum of Ion Channel Diseases Increase Further in the Near Future? **2002**, 212-218	
10	Catecholaminergic Polymorphic Ventricular Tachycardia: Another Inherited Arrhythmia? **2002**, 187-190	
9	The Long QT Syndrome. *Contemporary Cardiology*, **2003**, 169-185	0.1
8	Long QT Syndrome **2004**, 740-744	
7	Genetic Testing in the Long QT Syndrome: Development and Validation of an Efficient Approach to Genotyping in Clinical Practice. *Yearbook of Cardiology*, **2006**, 2006, 456-457	
6	Genetics of Inherited Arrhythmias **2007**, 502-513	
5	Catecholaminergic Polymorphic Ventricular Tachycardia. *Cardiac and Vascular Biology*, **2018**, 231-256	0.2
4	Combining Decision Support System-Generated Recommendations with Interactive Guideline Visualization for Better Informed Decisions. *Lecture Notes in Computer Science*, **2015**, 337-341	0.9
3	Catecholaminergic Polymorphic Ventricular Tachycardia **2013**, 551-560	

List of Publications

2 Inheritable Phenotypes Associated With Altered Intracellular Calcium Regulation **2014**, 521-528

1 Pathophysiology of Atrial Fibrillation11-16